Premium
“Double carbapenem” and oral fosfomycin for the treatment of complicated urinary tract infections caused by bla NDM ‐harboring Enterobacteriaceae in kidney transplantation
Author(s) -
Rosa Rossana,
Rudin Susan D.,
Rojas Laura J.,
Hujer Andrea M.,
PerezCardona Armando,
Perez Federico,
Bonomo Robert A.,
Martinez Octavio,
Abbo Lilian M.,
Camargo Jose F.
Publication year - 2018
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12795
Subject(s) - fosfomycin , enterobacteriaceae , medicine , carbapenem resistant enterobacteriaceae , urinary system , carbapenem , nephrotoxicity , kidney transplantation , antibiotics , microbiology and biotechnology , transplantation , kidney , escherichia coli , biology , biochemistry , gene
Abstract Infections with carbapenemase‐producing carbapenem‐resistant Enterobacteriaceae represent an emergent problem worldwide. Treatment of infections caused by New Delhi metallo‐beta‐lactamase ( NDM )‐harboring Enterobacteriaceae is particularly challenging as it frequently involves the use of nephrotoxic agents, which is problematic in kidney transplant recipients and non‐renal transplant patients with marginal kidney function. We present two cases of urinary tract infections caused by NDM ‐harboring Enterobacteriaceae successfully treated with a combination of “double carbapenem” and oral fosfomycin.